Engineering mammalian cell line for N-linked glycosylation control
Name
1251803194-MIT.pdf
Size
8.7 MB
Format
Adobe PDF
Checksum (MD5)
060938f01f2f2a5adcaad30a5efa213a
Author(s)
Jung, Giyoung.
Advisor(s)
Timothy K. Lu.
Date Issued
2021
Publisher
Massachusetts Institute of Technology
Abstract
N-linked glycosylation in monoclonal antibodies (mAbs) plays a critical role in their biological function, clinical efficacy, and safety. mAbs have highly conserved N-linked glycans at the Asn297 position of the Fc region affecting Fc-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Despites increasing efforts to develop strategies for glycoengineering, the lack of tools to precisely control mAb N-glycosylation has significantly hampered the production of more effective and safe antibodies. Here, we leverage synthetic biology to control mAbs fucosylation and galactosylation with small molecule inducible systems and synthetic miRNA regulators in engineered Chinese hamster ovary (CHO) cells. We achieved precise tuning of fucosylation (0-97%) and galactosylation (0-87%) levels with dose-dependent induction of two glycosyltransferases genes, FUT8 and [beta]4GALT1. Importantly, orthogonal and small molecule inducible gene expression enabled us to simultaneously and independently control levels of fucosylation and galactosylation. Next, we developed a system for intrinsic control of mAbs fucosylation, thereby eliminating the need for expensive small molecules. Using FUT8⁻/⁻ CHO cells, recombinant FUT8 expression levels were controlled by varying numbers of synthetic miRNA target sites at the 5' and 3' UTRs. Upon induction of miR-FF4, precise tuning of mAb fucosylation levels (0.9-98%) were achieved and mAb production remained stable for long-term experiments. The development of tools to control N-glycosylation levels of monoclonal antibodies will help to overcome existing bottlenecks in next-generation antibody engineering, thereby improving their clinical efficacy.
Description
Thesis: Ph. D., Harvard-MIT Program in Health Sciences and Technology, February, 2021
Cataloged from the official PDF version of thesis.
Includes bibliographical references (pages 101-109).
Subjects
Harvard--MIT Program in Health Sciences and Technology.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
MIT theses may be protected by copyright. Please reuse MIT thesis content according to the MIT Libraries Permissions Policy, which is available through the URL provided.
Persistent DSpace Link
